Sponsors (2)
The bill creates recurring, more-transparent stakeholder forums that can speed and clarify rare‑disease drug development for patients and researchers, but does so at modest taxpayer expense and with risks of FDA resource strain, conflicts of interest, and non‑binding outcomes for participants.
Patients with rare diseases will see clearer, better-aligned development paths and potentially faster approvals because stakeholder meetings aim to align trial designs, endpoints, and biomarker use.
Researchers and drug sponsors get structured, recurring forums (at least quarterly) to discuss scientific challenges and regulatory expectations, reducing development uncertainty and facilitating problem-solving across industry, academia, and FDA.
FDA must disclose whether meeting input was relevant to regulatory decisions and describe how it was incorporated, increasing accountability about how stakeholder input influenced approvals.
FDA review divisions may need to divert staff time and resources to participate in meetings, which could slow other review workloads and affect patients awaiting reviews.
Industry and patient-group participation could introduce conflicts of interest that influence recommendations or public perceptions of advice despite COI policies, potentially undermining trust in outcomes.
Because the meetings are explicitly non-binding and do not create legal consultation rights, stakeholders (researchers, sponsors, patients) may spend time and resources with no guaranteed regulatory impact.
Based on analysis of 2 sections of legislative text.
Introduced March 3, 2025 by Amy Klobuchar · Last progress March 3, 2025
Creates a program for externally led, science-focused drug development meetings about rare diseases that the Department of Health and Human Services (HHS) must arrange through a designated Foundation. The Foundation will run at least four meetings a year on different rare diseases, form a multistakeholder steering committee, plan meetings with FDA and other stakeholders, and post transcripts and a summary analysis publicly within 180 days after each meeting. Requires FDA review-division staff to take part in meetings, directs the agency to disclose when a relevant meeting occurred and how its input was used in certain drug approvals, and mandates annual reports to Congress on meeting activity and effects on FDA workload. Authorizes modest funding ($1 million per year for each of two program components) for fiscal years 2025–2029 and allows the Foundation to seek other contributions.